Doxorubicin (PEGASEMP/encapsulated nanoparticle formulation, cancer)

N/A

Report date: 2025/12/12 17:31:45

Base Information

Drug NameDoxorubicin (PEGASEMP/encapsulated nanoparticle formulation, cancer)
Drug Alias NameDoxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolinPEGASEMP
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionDNA polymerase III inhibitorsNucleolin inhibitors
TargetsDNA polymerase IIINucleolin
Therapy Area/IndicationsBreast NeoplasmsMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A